How Biosimilars Are Disrupting Blockbuster Biologics

Episode 13 of Biotech Business explores the rise of biosimilars—near-copies of complex biologic drugs that are shaking up the $300 billion biologics market. Lucas and Luna break down the science, economics, and regulatory landscape, using the case of AbbVie's Humira, which lost over 50 percent of its market share to biosimilars within two years of patent expiration. They discuss why biosimilars are cheaper to develop than new drugs but still cost hundreds of millions to bring to market, how the FDA's approval pathway has evolved, and why startups like Coherus BioSciences and Samsung Bioepis are leading the charge. The episode examines the tension between innovation and access, and what the biosimilar wave means for drug pricing, pharma business models, and patient care. A clear, specific look at one of the most consequential shifts in modern drug economics. #Biosimilars #Biologics #Humira #AbbVie #CoherusBioSciences #SamsungBioepis #FDA #DrugPricing #BiotechBusiness #Biotech #Pharma #PatentExpiration #BiotechStartups #DrugDevelopment #HealthcareEconomics #Business #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo